MARKET

AKBA

AKBA

Akebia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.080
+0.180
+6.21%
Opening 12:22 05/11 EDT
OPEN
2.810
PREV CLOSE
2.900
HIGH
3.090
LOW
2.750
VOLUME
2.16M
TURNOVER
--
52 WEEK HIGH
13.71
52 WEEK LOW
2.090
MARKET CAP
492.52M
P/E (TTM)
-1.1101
1D
5D
1M
3M
1Y
5Y
10-Q: AKEBIA THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following information should...
Edgar Online - (EDG = 10Q, 10K) · 20h ago
Akebia Therapeutics (AKBA) Gets a Buy Rating from Mizuho Securities
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Akebia Therapeutics (AKBA), with a price target of $6.00. The
SmarterAnalyst · 20h ago
Akebia Therapeutics (AKBA) Receives a Buy from Needham
Needham analyst Chad Messer maintained a Buy rating on Akebia Therapeutics (AKBA) today and set a price target of $10.00. The company's shares closed last
SmarterAnalyst · 23h ago
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -36.36% and 19.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
8-K: Akebia Therapeutics, Inc.
(EDGAR Online via COMTEX) -- false 0001517022 0001517022 2021-05-10 2021-05-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
Recap: Akebia Therapeutics Q1 Earnings
  Shares of Akebia Therapeutics (NASDAQ:AKBA) fell 1.0% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 4.26% year over year to ($0.45), which missed the estimate of ($0.36).
Benzinga · 1d ago
Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent corporat...
PR Newswire · 1d ago
Akebia Therapeutics, Inc. to Host Earnings Call
ACCESSWIRE · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKBA. Analyze the recent business situations of Akebia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKBA stock price target is 6.71 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 246
Institutional Holdings: 105.83M
% Owned: 66.18%
Shares Outstanding: 159.91M
TypeInstitutionsShares
Increased
46
23.61M
New
17
5.80M
Decreased
52
11.58M
Sold Out
37
16.81M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Adrian Adams
President/Chief Executive Officer/Director
John Butler
Chief Financial Officer/Senior Vice President/Treasurer
David Spellman
Chief Operating Officer/Senior Vice President
Michel Dahan
Senior Vice President/Secretary
Nicole Hadas
Senior Vice President
Steven Burke
Senior Vice President
Dell Faulkingham
Director
LeAnne Zumwalt
Independent Director
Mark Enyedy
Independent Director
Steven Gilman
Independent Director
Maxine Gowen
Independent Director
Michael Heffernan
Independent Director
Michael Rogers
Independent Director
Cynthia Smith
Independent Director
Myles Wolf
No Data
  • All
  • Financials
  • Insiders
More
About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.